Leronlimab: all 25 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP TrialNot yet recruitingNCT07842965Phase 1
- Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's DiseaseRecruitingNCT07553338Phase 2
- An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 StudyTerminatedNCT05271370Phase 2/3Results posted
- Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19CompletedNCT04678830Phase 2Results posted
- Leronlimab (PRO 140) in Patients With Nonalcoholic SteatohepatitisCompletedNCT04521114Phase 2Results posted
- Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid TumorsCompletedNCT04504942Phase 2Results posted
- Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19CompletedNCT04347239Phase 2Results posted
- Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19CompletedNCT04343651Phase 2Results posted
- PRO 140 in Treatment-Experienced HIV-1 SubjectsCompletedNCT03902522Phase 2/3Results posted
- Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBCTerminatedNCT03838367Phase 1/2Results posted
- An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label StudyTerminatedNCT02990858Phase 2/3Results posted
- Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 InfectionCompletedNCT02859961Phase 2/3Results posted
- A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell TransplantationTerminatedNCT02737306Phase 2Results posted
- Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140CompletedNCT02483078Phase 2/3Results posted
- An Extension of Protocol PRO 140_CD01 StudyTerminatedNCT02355184Phase 2Results posted
- Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 InfectionCompletedNCT02175680Phase 2Results posted
- Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 InfectionCompletedNCT00642707Phase 2Results posted
- PRO 140 by IV Administration in Adults With HIV-1 InfectionCompletedNCT00613379Phase 2Results posted
- Safety and Tolerability of PRO 140 in HIV Uninfected Male VolunteersCompletedNCT00110591Phase 1Results posted
- CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched RegimenActive, not recruitingNCT06699836Phase 2
- Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane OxygenationSuspendedNCT04901689Phase 3
- Leronlimab in Moderately Ill Patients With COVID-19 PneumoniaSuspendedNCT04901676Phase 3
- PRO 140 for Human Immunodeficiency VirusWithdrawnNCT02438345Phase 2
- PRO 140 for Human Immunodeficiency Virus InfectionWithdrawnNCT02257788Phase 2
- A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor AdherenceWithdrawnNCT01272258Phase 2